MedTrace Logo

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

NCT06047210 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.

Conditions

  • Hemophagocytic Lymphohistiocytoses

Interventions

OTHER

Blood Draws Data Collection

Sponsors & Collaborators

  • Brigham and Women's Hospital

    collaborator OTHER

  • Harvard Medical School (HMS and HSDM)

    collaborator OTHER

  • Swedish Orphan Biovitrum

    lead INDUSTRY

Principal Investigators

  • Nancy Berliner, MD · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-14
Primary Completion
2019-10-30
Completion
2019-10-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06047210 on ClinicalTrials.gov